Short Bowel Syndrome Market Anticipated Surpassing ~USD 4 Billion by 2035

Buy Now

An extensive study of propelling opportunities in, “Short Bowel Syndrome Market Size, Share & Trends Analysis Report by Disease Type/Etiology, Acquired Short Bowel), Severity/Classification, Treatment Type, Route of Administration, Patient Age Group, Distribution Channel, End-Users and Geography (North America, Europe, Asia Pacific, Middle East, Africa, and South America) – Global Industry Data, Trends, and Forecasts, 2025–2035” A comprehensive report of growing market landscapes in the short bowel syndrome sector uncovering key growth drivers including niche market leadership, technology-enabled distribution, and increasing consumer needs supporting short bowel syndrome potential to scale globally.

Global Short Bowel Syndrome Market Forecast 2035:

According to the report, the short bowel syndrome market is anticipated to grow from USD 1.6 Billion in 2025 to USD 4.1 Billion in 2035 at a CAGR of 9.8% during the forecast. The short bowel syndrome (SBS) market is seeing significant expansion and greater demand due to improvements in regenerative medicine, increased prevalence of gastrointestinal disorders, and the utilization of digital health technologies across North America and Europe. Major pharmaceutical and biotech businesses are encouraging new developments in remote patient management such as virtual consultations, artificial intelligence monitoring of treatment, data-driven clinical decision support platforms, and so on, therefore improving access to and efficiency of SBS care.

Connected monitoring and tele-SBS platforms are gaining momentum for healthcare providers to develop personalized and scalable care models - especially with the increased global demand for specialized gastrointestinal therapies. The ongoing post-COVID emphasis on home-based care is pushing this paradigm as patients seek clinical care without physical contact and want their basic care delivered continuously live and share their observations with healthcare practitioners supported by streaming real-time data.

In addition, the use of virtual reality (VR) and simulation technologies as learning platforms in clinical training is helping develop a workforce of capable gastrointestinal care providers and facilitate next steps in precision-based treatment. Rising investment in cybersecurity infrastructure also still provides confidence and maintainability in regulatory compliance for data privacy and protection of sensitive patient information harvested through digital health technologies.

“Key Driver, Restraint, and Growth Opportunity Defining the Global Short Bowel Syndrome Market”

The worldwide short bowel syndrome (SBS) market keeps expanding, supported by an increased awareness of the disease, advancements in nutritional and pharmacological therapies, and shifts toward digital patient-centric care models. Developments in tele-gastroenterology, AI-assisted treatment planning, remote monitoring, and precision nutrition afford a more personalized and convenient approach to care, particularly as home-based and virtual care begin to take hold.

However, ongoing growth is constrained by the high expense of therapy, challenges with insurance reimbursement, and restricted access to specialty clinicians, as well as fragmented follow-up care, and poor patient adherence, especially for patients on home parenteral nutrition. These factors impede the continuity of care and the outcomes of therapy.

Even with these constraints of growth, patient expectations are evolving, and the rapid interjection of digital health along with the growing multidisciplinary models of care offer positive opportunities for growth. Continued investment in virtual care infrastructure, in clinical tools that are AI-enabled, and real training for specialists will be necessary to help enhance care, improve patient outcomes, and unlock the potential opportunities presented in the SBS market.

"Impact of Global Tariff Policies on the Global Short Bowel Syndrome Market Growth and Strategy"

Tariffs on international trade are an escalating strain on the short bowel syndrome (SBS) market, as tariffs raise the cost of crucial items and materials, such as parenteral nutrition products, medical devices, infusion pumps, and specialized nutritional supplements. Tariffs on imported products from major manufacturing regions like China, India, and Mexico could ultimately drive up the costs of production and distribution in the SBS treatment ecosystem. Increased costs may ultimately impact affordability and access to care, and this impact will be particularly pronounced in cost-sensitive healthcare markets.
In response to this pressure, manufacturers and suppliers are focusing on supply chain diversification with investments in domestic manufacturing capabilities and industrial advancements to increase efficiencies and decrease the reliance on imported components. In addition, manufacturers and suppliers engage digital supply chain management techniques, automation, and predictive analysis, to optimize logistics and improve procurement practices.
Since, global trade policy and regulations (tariffs) continue to evolve, government regulators and policymakers should consider the potential impact on the availability, affordability, and continuity of care in connection with the SBS market - and ultimately, that cost should not be a barrier to patient access to life-sustaining treatment.

Expansion of Global Short Bowel Syndrome Market

“Advancements in Therapies and Increasing Patient Awareness Drive Growth in the Short Bowel Syndrome Market”

The short bowel syndrome (SBS) market is growing rapidly fueled by advancements in therapies and emerging awareness among patients for support. One of the drivers is the emergence of new pharmacological therapies/biologics that facilitate nutrient absorption and reduce dependency on parenteral nutrition. The advancements and availability of these products are extending treatment options beyond traditional surgical procedures and to a wider demographic of the SBS population, including older individuals and frail patients, allowing them to manage their SBS and improve their quality of life.
Growing patient awareness and education about SBS is also contributing to market growth. Awareness campaigns, patient advocacy groups, and online education for patients and caregivers are allowing patients and other advocates to recognize symptoms sooner and pursue treatment sooner. Increased patient education is a call to action, as proactive disease management will promote the uptake of newer and old therapy for SBS to achieve better outcomes.
Technological advancements in mode of therapy delivery and monitoring is driving innovation in the SBS market. New diagnostic modalities, remote patient monitoring, and artificial intelligence for treatment planning will enhance a physician’s capacity to tailor therapies for individual patients. Telehealth platforms and home-based care, which allow for treatment for patients in underserved or distant locations will also become more feasible and available.

Regional Analysis of Global Short Bowel Syndrome Market

North America is the foremost region in the short bowel syndrome market with a high level of healthcare infrastructure, overall patient awareness, and faster adoption and use of new therapies. To this end, in early 2025, Takeda Pharmaceuticals will release a next-generation SBS biologic therapy in U.S. clinics, featuring a digital patient monitoring tool to follow both nutritional status and compliance to treatment.
Asia Pacific is also showing rapid growth, driven by increasing health care expenditure; improved access to specialized care; and a higher level of awareness of SBS. In early 2025, Zealand Pharma will partner with leading hospitals in Japan and India to launch its novel SBS therapies with telehealth monitoring systems to allow greater access to therapy for patients within both urban and rural communities.
Europe is seeing steady growth supported by public health care initiatives and the improvement to patient outcomes. In late 2024, NPS Pharmaceuticals (grouped under Shire) will become more readily available to UK, German, and French patients by expanding access to its SBS treatment program with digital nutrition monitoring tools and remote patient support services to enable longer-packaged care and management.

Key players in the global short bowel syndrome market include prominent companies such as Abbott Laboratories, Ardelyx Inc., B. Braun Melsungen AG, Baxter International Inc., Danone Nutricia, Emmaus Life Sciences, Fresenius Kabi AG, GlyPharma Therapeutic Inc., Grifols S.A., Helsinn Healthcare SA, Ironwood Pharmaceuticals Inc., Medinova AG, Merck & Co. Inc., Naia Rare Diseases, Nestlé Health Science, Novartis AG, Nutrinia Ltd, Otsuka Pharmaceutical Co. Ltd., OxThera AB, Pfizer Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, VectivBio AG, Zealand Pharma A/S, and other key players contributing to market growth through innovation, strategic partnerships, and global expansion.

The global short bowel syndrome market has been segmented as follows:

Global Short Bowel Syndrome Market Analysis, by Disease Type/Etiology

Congenital Short Bowel Syndrome
- Gastroschisis
- Intestinal atresia
- Midgut volvulus
- Others
Acquired Short Bowel Syndrome
- Crohn's disease-related
- Mesenteric ischemia-related
- Trauma-induced
- Radiation enteritis-related
- Malignancy-related
- Others

Global Short Bowel Syndrome Market Analysis, by Severity/Classification

Type I
Type II
Type III
Ultra-Short Bowel Syndrome

Global Short Bowel Syndrome Market Analysis, by Treatment Type

Pharmacological Treatment
- GLP-2 analogs (Teduglutide)
- Growth hormone therapy
- Glutamine supplementation
- Proton pump inhibitors
- H2 receptor antagonists
- Antimotility agents
- Antibiotics
- Others
Nutritional Support
- Parenteral nutrition (PN)
- Enteral nutrition
- Oral rehydration solutions
- Others
Surgical Interventions
- Intestinal lengthening procedures
- Small bowel transplantation
- Autologous gastrointestinal reconstruction
- Others

Global Short Bowel Syndrome Market Analysis, by Route of Administration

Oral
Subcutaneous
Intravenous
Enteral

Global Short Bowel Syndrome Market Analysis, by Patient Age Group

Pediatric (0-17 years)
Adult (18-64 years)
Geriatric (65+ years)

Global Short Bowel Syndrome Market Analysis, by Distribution Channel

Hospital Pharmacies
Retail Pharmacies
Specialty Pharmacies
Online Pharmacies
Home Healthcare Services

Global Short Bowel Syndrome Market Analysis, by End-Users

Hospitals
Specialty Clinics
Home Healthcare Settings
Ambulatory Surgical Centers
Rehabilitation Centers
Research Institutions
Others

Global Short Bowel Syndrome Market Analysis, by Region

North America
Europe
Asia Pacific
Middle East
Africa
South America

About Us

MarketGenics is a global market research and management consulting company empowering decision makers from startups, Fortune 500 companies, non-profit organizations, universities and government institutions. Our main goal is to assist and partner organizations to make lasting strategic improvements and realize growth targets. Our industry research reports are designed to provide granular quantitative information, combined with key industry insights, aimed at assisting sustainable organizational development.

We serve clients on every aspect of strategy, including product development, application modeling, exploring new markets and tapping into niche growth opportunities.

Contact US

USA Address:

800 N King Street Suite 304 #4208 Wilmington, DE 19801 United States.

+1(302)303-2617

info@marketgenics.co

India Address:

3rd floor, Indeco Equinox, Baner Road, Baner, Pune, Maharashtra 411045 India.

sales@marketgenics.co

Table of Contents

1. Research Methodology and Assumptions
- 1.1. Definitions
- 1.2. Research Design and Approach
- 1.3. Data Collection Methods
- 1.4. Base Estimates and Calculations
- 1.5. Forecasting Models
  - 1.5.1. Key Forecast Factors & Impact Analysis
- 1.6. Secondary Research
  - 1.6.1. Open Sources
  - 1.6.2. Paid Databases
  - 1.6.3. Associations
- 1.7. Primary Research
  - 1.7.1. Primary Sources
  - 1.7.2. Primary Interviews with Stakeholders across Ecosystem
2. Executive Summary
- 2.1. Global Short Bowel Syndrome Market Outlook
  - 2.1.1. Global Short Bowel Syndrome Market Size (Value - USD Bn), and Forecasts, 2021-2035
  - 2.1.2. Compounded Annual Growth Rate Analysis
  - 2.1.3. Growth Opportunity Analysis
  - 2.1.4. Segmental Share Analysis
  - 2.1.5. Geographical Share Analysis
- 2.2. Market Analysis and Facts
- 2.3. Supply-Demand Analysis
- 2.4. Competitive Benchmarking
- 2.5. Go-to- Market Strategy
  - 2.5.1. Customer/ End-use Industry Assessment
  - 2.5.2. Growth Opportunity Data, 2025-2035
    - 2.5.2.1. Regional Data
    - 2.5.2.2. Country Data
    - 2.5.2.3. Segmental Data
  - 2.5.3. Identification of Potential Market Spaces
  - 2.5.4. GAP Analysis
  - 2.5.5. Potential Attractive Price Points
  - 2.5.6. Prevailing Market Risks & Challenges
  - 2.5.7. Preferred Sales & Marketing Strategies
  - 2.5.8. Key Recommendations and Analysis
  - 2.5.9. A Way Forward
3. Industry Data and Premium Insights
- 3.1. Global Short Bowel Syndrome Industry Overview, 2025
  - 3.1.1. Healthcare & Pharmaceutical Industry Analysis
  - 3.1.2. Key Trends for Healthcare & Pharmaceutical Industry
  - 3.1.3. Regional Distribution for Healthcare & Pharmaceutical Industry
- 3.2. Supplier Customer Data
- 3.3. Source Roadmap and Developments
- 3.4. Trade Analysis
  - 3.4.1. Import & Export Analysis, 2025
  - 3.4.2. Top Importing Countries
  - 3.4.3. Top Exporting Countries
- 3.5. Trump Tariff Impact Analysis
  - 3.5.1. Manufacturer
  - 3.5.2. Supply Chain
  - 3.5.3. End Consumer
- 3.6. Raw Material Analysis
4. Market Overview
- 4.1. Market Dynamics
  - 4.1.1. Drivers
    - 4.1.1.1. Rising Demand for Pharmacological and Minimally Invasive Therapies Supporting Short Bowel Syndrome Market
  - 4.1.2. Restraints
    - 4.1.2.1. High Treatment Costs and Limited Reimbursement Coverage Limiting Widespread Adoption of Advanced Short Bowel Syndrome
- 4.2. Key Trend Analysis
- 4.3. Regulatory Framework
  - 4.3.1. Key Regulations, Norms, and Subsidies, by Key Countries
  - 4.3.2. Tariffs and Standards
  - 4.3.3. Impact Analysis of Regulations on the Market
- 4.4. Value Chain Analysis
  - 4.4.1. R&D & Clinical Development
  - 4.4.2. Regulatory & Compliance
  - 4.4.3. Manufacturing & Distribution
  - 4.4.4. Marketing, Awareness & Patient Support
  - 4.4.5. Healthcare Delivery & Post-Market Feedback
- 4.5. Cost Structure Analysis
  - 4.5.1. Parameter’s Share for Cost Associated
  - 4.5.2. COGP vs COGS
  - 4.5.3. Profit Margin Analysis
- 4.6. Pricing Analysis
  - 4.6.1. Regional Pricing Analysis
  - 4.6.2. Segmental Pricing Trends
  - 4.6.3. Factors Influencing Pricing
- 4.7. Porter’s Five Forces Analysis
- 4.8. PESTEL Analysis
- 4.9. Global Short Bowel Syndrome Market Demand
  - 4.9.1. Historical Market Size – (Value - USD Bn), 2021-2024
  - 4.9.2. Current and Future Market Size – (Value - USD Bn), 2025–2035
    - 4.9.2.1. Y-o-Y Growth Trends
    - 4.9.2.2. Absolute $ Opportunity Assessment
5. Competition Landscape
- 5.1. Competition structure
  - 5.1.1. Fragmented v/s consolidated
- 5.2. Company Share Analysis, 2025
  - 5.2.1. Global Company Market Share
  - 5.2.2. By Region
    - 5.2.2.1. North America
    - 5.2.2.2. Europe
    - 5.2.2.3. Asia Pacific
    - 5.2.2.4. Middle East
    - 5.2.2.5. Africa
    - 5.2.2.6. South America
- 5.3. Product Comparison Matrix
  - 5.3.1. Specifications
  - 5.3.2. Market Positioning
  - 5.3.3. Pricing
6. Global Short Bowel Syndrome Market Analysis, by Disease Type/Etiology
- 6.1. Key Segment Analysis
- 6.2. Global Short Bowel Syndrome Market Size (Value - USD Bn), Analysis, and Forecasts, by Disease Type/Etiology, 2021-2035
  - 6.2.1. Congenital Short Bowel Syndrome
    - 6.2.1.1. Gastroschisis
    - 6.2.1.2. Intestinal atresia
    - 6.2.1.3. Midgut volvulus
    - 6.2.1.4. Others
  - 6.2.2. Acquired Short Bowel Syndrome
    - 6.2.2.1. Crohn's disease-related
    - 6.2.2.2. Mesenteric ischemia-related
    - 6.2.2.3. Trauma-induced
    - 6.2.2.4. Radiation enteritis-related
    - 6.2.2.5. Malignancy-related
    - 6.2.2.6. Others
7. Global Short Bowel Syndrome Market Analysis, by Severity/Classification
- 7.1. Key Segment Analysis
- 7.2. Global Short Bowel Syndrome Market Size (Value - USD Bn), Analysis, and Forecasts, by Severity/Classification, 2021-2035
  - 7.2.1. Type I
  - 7.2.2. Type II
  - 7.2.3. Type III
  - 7.2.4. Ultra-Short Bowel Syndrome
8. Global Short Bowel Syndrome Market Analysis, by Treatment Type
- 8.1. Key Segment Analysis
- 8.2. Global Short Bowel Syndrome Market Size (Value - USD Bn), Analysis, and Forecasts, by Treatment Type, 2021-2035
  - 8.2.1. Pharmacological Treatment
    - 8.2.1.1. GLP-2 analogs (Teduglutide)
    - 8.2.1.2. Growth hormone therapy
    - 8.2.1.3. Glutamine supplementation
    - 8.2.1.4. Proton pump inhibitors
    - 8.2.1.5. H2 receptor antagonists
    - 8.2.1.6. Antimotility agents
    - 8.2.1.7. Antibiotics
    - 8.2.1.8. Others
  - 8.2.2. Nutritional Support
    - 8.2.2.1. Parenteral nutrition (PN)
    - 8.2.2.2. Enteral nutrition
    - 8.2.2.3. Oral rehydration solutions
    - 8.2.2.4. Others
  - 8.2.3. Surgical Interventions
    - 8.2.3.1. Intestinal lengthening procedures
    - 8.2.3.2. Small bowel transplantation
    - 8.2.3.3. Autologous gastrointestinal reconstruction
    - 8.2.3.4. Others
9. Global Short Bowel Syndrome Market Analysis, by Route of Administration
- 9.1. Key Segment Analysis
- 9.2. Global Short Bowel Syndrome Market Size (Value - USD Bn), Analysis, and Forecasts, by Route of Administration, 2021-2035
  - 9.2.1. Oral
  - 9.2.2. Subcutaneous
  - 9.2.3. Intravenous
  - 9.2.4. Enteral
10. Global Short Bowel Syndrome Market Analysis, by Patient Age Group
- 10.1. Key Segment Analysis
- 10.2. Global Short Bowel Syndrome Market Size (Value - USD Bn), Analysis, and Forecasts, by Patient Age Group, 2021-2035
  - 10.2.1. Pediatric (0-17 years)
  - 10.2.2. Adult (18-64 years)
  - 10.2.3. Geriatric (65+ years)
11. Global Short Bowel Syndrome Market Analysis, by Distribution Channel
- 11.1. Key Segment Analysis
- 11.2. Global Short Bowel Syndrome Market Size (Value - USD Bn), Analysis, and Forecasts, by Distribution Channel, 2021-2035
  - 11.2.1. Hospital Pharmacies
  - 11.2.2. Retail Pharmacies
  - 11.2.3. Specialty Pharmacies
  - 11.2.4. Online Pharmacies
  - 11.2.5. Home Healthcare Services
12. Global Short Bowel Syndrome Market Analysis, by End-Users
- 12.1. Key Segment Analysis
- 12.2. Global Short Bowel Syndrome Market Size (Value - USD Bn), Analysis, and Forecasts, by End-Users, 2021-2035
  - 12.2.1. Hospitals
  - 12.2.2. Specialty Clinics
  - 12.2.3. Home Healthcare Settings
  - 12.2.4. Ambulatory Surgical Centers
  - 12.2.5. Rehabilitation Centers
  - 12.2.6. Research Institutions
  - 12.2.7. Others
13. Global Short Bowel Syndrome Market Analysis and Forecasts, by Region
- 13.1. Key Findings
- 13.2. Global Short Bowel Syndrome Market Size (Value - USD Bn), Analysis, and Forecasts, by Region, 2021-2035
  - 13.2.1. North America
  - 13.2.2. Europe
  - 13.2.3. Asia Pacific
  - 13.2.4. Middle East
  - 13.2.5. Africa
  - 13.2.6. South America
14. North America Global Short Bowel Syndrome Market Analysis
- 14.1. Key Segment Analysis
- 14.2. Regional Snapshot
- 14.3. North America Global Short Bowel Syndrome Market Size (Value - USD Bn), Analysis, and Forecasts, 2021-2035
  - 14.3.1. Disease Type/Etiology
  - 14.3.2. Severity/Classification
  - 14.3.3. Treatment Type
  - 14.3.4. Route of Administration
  - 14.3.5. Patient Age Group
  - 14.3.6. Distribution Channel
  - 14.3.7. End-Users
  - 14.3.8. Country
    - 14.3.8.1. USA
    - 14.3.8.2. Canada
    - 14.3.8.3. Mexico
- 14.4. USA Global Short Bowel Syndrome Market
  - 14.4.1. Country Segmental Analysis
  - 14.4.2. Disease Type/Etiology
  - 14.4.3. Severity/Classification
  - 14.4.4. Treatment Type
  - 14.4.5. Route of Administration
  - 14.4.6. Patient Age Group
  - 14.4.7. Distribution Channel
  - 14.4.8. End-Users
- 14.5. Canada Global Short Bowel Syndrome Market
  - 14.5.1. Country Segmental Analysis
  - 14.5.2. Disease Type/Etiology
  - 14.5.3. Severity/Classification
  - 14.5.4. Treatment Type
  - 14.5.5. Route of Administration
  - 14.5.6. Patient Age Group
  - 14.5.7. Distribution Channel
  - 14.5.8. End-Users
- 14.6. Mexico Global Short Bowel Syndrome Market
  - 14.6.1. Country Segmental Analysis
  - 14.6.2. Disease Type/Etiology
  - 14.6.3. Severity/Classification
  - 14.6.4. Treatment Type
  - 14.6.5. Route of Administration
  - 14.6.6. Patient Age Group
  - 14.6.7. Distribution Channel
  - 14.6.8. End-Users
15. Europe Global Short Bowel Syndrome Market Analysis
- 15.1. Key Segment Analysis
- 15.2. Regional Snapshot
- 15.3. Europe Global Short Bowel Syndrome Market Size (Value - USD Bn), Analysis, and Forecasts, 2021-2035
  - 15.3.1. Disease Type/Etiology
  - 15.3.2. Severity/Classification
  - 15.3.3. Treatment Type
  - 15.3.4. Route of Administration
  - 15.3.5. Patient Age Group
  - 15.3.6. Distribution Channel
  - 15.3.7. End-Users
  - 15.3.8. Country
    - 15.3.8.1. Germany
    - 15.3.8.2. United Kingdom
    - 15.3.8.3. France
    - 15.3.8.4. Italy
    - 15.3.8.5. Spain
    - 15.3.8.6. Netherlands
    - 15.3.8.7. Nordic Countries
    - 15.3.8.8. Poland
    - 15.3.8.9. Russia & CIS
    - 15.3.8.10. Rest of Europe
- 15.4. Germany Global Short Bowel Syndrome Market
  - 15.4.1. Country Segmental Analysis
  - 15.4.2. Disease Type/Etiology
  - 15.4.3. Severity/Classification
  - 15.4.4. Treatment Type
  - 15.4.5. Route of Administration
  - 15.4.6. Patient Age Group
  - 15.4.7. Distribution Channel
  - 15.4.8. End-Users
- 15.5. United Kingdom Global Short Bowel Syndrome Market
  - 15.5.1. Country Segmental Analysis
  - 15.5.2. Disease Type/Etiology
  - 15.5.3. Severity/Classification
  - 15.5.4. Treatment Type
  - 15.5.5. Route of Administration
  - 15.5.6. Patient Age Group
  - 15.5.7. Distribution Channel
  - 15.5.8. End-Users
- 15.6. France Global Short Bowel Syndrome Market
  - 15.6.1. Country Segmental Analysis
  - 15.6.2. Disease Type/Etiology
  - 15.6.3. Severity/Classification
  - 15.6.4. Treatment Type
  - 15.6.5. Route of Administration
  - 15.6.6. Patient Age Group
  - 15.6.7. Distribution Channel
  - 15.6.8. End-Users
- 15.7. Italy Global Short Bowel Syndrome Market
  - 15.7.1. Country Segmental Analysis
  - 15.7.2. Disease Type/Etiology
  - 15.7.3. Severity/Classification
  - 15.7.4. Treatment Type
  - 15.7.5. Route of Administration
  - 15.7.6. Patient Age Group
  - 15.7.7. Distribution Channel
  - 15.7.8. End-Users
- 15.8. Spain Global Short Bowel Syndrome Market
  - 15.8.1. Country Segmental Analysis
  - 15.8.2. Disease Type/Etiology
  - 15.8.3. Severity/Classification
  - 15.8.4. Treatment Type
  - 15.8.5. Route of Administration
  - 15.8.6. Patient Age Group
  - 15.8.7. Distribution Channel
  - 15.8.8. End-Users
- 15.9. Netherlands Global Short Bowel Syndrome Market
  - 15.9.1. Country Segmental Analysis
  - 15.9.2. Disease Type/Etiology
  - 15.9.3. Severity/Classification
  - 15.9.4. Treatment Type
  - 15.9.5. Route of Administration
  - 15.9.6. Patient Age Group
  - 15.9.7. Distribution Channel
  - 15.9.8. End-Users
- 15.10. Nordic Countries Global Short Bowel Syndrome Market
  - 15.10.1. Country Segmental Analysis
  - 15.10.2. Disease Type/Etiology
  - 15.10.3. Severity/Classification
  - 15.10.4. Treatment Type
  - 15.10.5. Route of Administration
  - 15.10.6. Patient Age Group
  - 15.10.7. Distribution Channel
  - 15.10.8. End-Users
- 15.11. Poland Global Short Bowel Syndrome Market
  - 15.11.1. Country Segmental Analysis
  - 15.11.2. Disease Type/Etiology
  - 15.11.3. Severity/Classification
  - 15.11.4. Treatment Type
  - 15.11.5. Route of Administration
  - 15.11.6. Patient Age Group
  - 15.11.7. Distribution Channel
  - 15.11.8. End-Users
- 15.12. Russia & CIS Global Short Bowel Syndrome Market
  - 15.12.1. Country Segmental Analysis
  - 15.12.2. Disease Type/Etiology
  - 15.12.3. Severity/Classification
  - 15.12.4. Treatment Type
  - 15.12.5. Route of Administration
  - 15.12.6. Patient Age Group
  - 15.12.7. Distribution Channel
  - 15.12.8. End-Users
- 15.13. Rest of Europe Global Short Bowel Syndrome Market
  - 15.13.1. Country Segmental Analysis
  - 15.13.2. Disease Type/Etiology
  - 15.13.3. Severity/Classification
  - 15.13.4. Treatment Type
  - 15.13.5. Route of Administration
  - 15.13.6. Patient Age Group
  - 15.13.7. Distribution Channel
  - 15.13.8. End-Users
16. Asia Pacific Global Short Bowel Syndrome Market Analysis
- 16.1. Key Segment Analysis
- 16.2. Regional Snapshot
- 16.3. East Asia Global Short Bowel Syndrome Market Size (Value - USD Bn), Analysis, and Forecasts, 2021-2035
  - 16.3.1. Disease Type/Etiology
  - 16.3.2. Severity/Classification
  - 16.3.3. Treatment Type
  - 16.3.4. Route of Administration
  - 16.3.5. Patient Age Group
  - 16.3.6. Distribution Channel
  - 16.3.7. End-Users
  - 16.3.8. Country
    - 16.3.8.1. China
    - 16.3.8.2. India
    - 16.3.8.3. Japan
    - 16.3.8.4. South Korea
    - 16.3.8.5. Australia and New Zealand
    - 16.3.8.6. Indonesia
    - 16.3.8.7. Malaysia
    - 16.3.8.8. Thailand
    - 16.3.8.9. Vietnam
    - 16.3.8.10. Rest of Asia-Pacific
- 16.4. China Global Short Bowel Syndrome Market
  - 16.4.1. Country Segmental Analysis
  - 16.4.2. Disease Type/Etiology
  - 16.4.3. Severity/Classification
  - 16.4.4. Treatment Type
  - 16.4.5. Route of Administration
  - 16.4.6. Patient Age Group
  - 16.4.7. Distribution Channel
  - 16.4.8. End-Users
- 16.5. India Global Short Bowel Syndrome Market
  - 16.5.1. Country Segmental Analysis
  - 16.5.2. Disease Type/Etiology
  - 16.5.3. Severity/Classification
  - 16.5.4. Treatment Type
  - 16.5.5. Route of Administration
  - 16.5.6. Patient Age Group
  - 16.5.7. Distribution Channel
  - 16.5.8. End-Users
- 16.6. Japan Global Short Bowel Syndrome Market
  - 16.6.1. Country Segmental Analysis
  - 16.6.2. Disease Type/Etiology
  - 16.6.3. Severity/Classification
  - 16.6.4. Treatment Type
  - 16.6.5. Route of Administration
  - 16.6.6. Patient Age Group
  - 16.6.7. Distribution Channel
  - 16.6.8. End-Users
- 16.7. South Korea Global Short Bowel Syndrome Market
  - 16.7.1. Country Segmental Analysis
  - 16.7.2. Disease Type/Etiology
  - 16.7.3. Severity/Classification
  - 16.7.4. Treatment Type
  - 16.7.5. Route of Administration
  - 16.7.6. Patient Age Group
  - 16.7.7. Distribution Channel
  - 16.7.8. End-Users
- 16.8. Australia and New Zealand Global Short Bowel Syndrome Market
  - 16.8.1. Country Segmental Analysis
  - 16.8.2. Disease Type/Etiology
  - 16.8.3. Severity/Classification
  - 16.8.4. Treatment Type
  - 16.8.5. Route of Administration
  - 16.8.6. Patient Age Group
  - 16.8.7. Distribution Channel
  - 16.8.8. End-Users
- 16.9. Indonesia Global Short Bowel Syndrome Market
  - 16.9.1. Country Segmental Analysis
  - 16.9.2. Disease Type/Etiology
  - 16.9.3. Severity/Classification
  - 16.9.4. Treatment Type
  - 16.9.5. Route of Administration
  - 16.9.6. Patient Age Group
  - 16.9.7. Distribution Channel
  - 16.9.8. End-Users
- 16.10. Malaysia Global Short Bowel Syndrome Market
  - 16.10.1. Country Segmental Analysis
  - 16.10.2. Disease Type/Etiology
  - 16.10.3. Severity/Classification
  - 16.10.4. Treatment Type
  - 16.10.5. Route of Administration
  - 16.10.6. Patient Age Group
  - 16.10.7. Distribution Channel
  - 16.10.8. End-Users
- 16.11. Thailand Global Short Bowel Syndrome Market
  - 16.11.1. Country Segmental Analysis
  - 16.11.2. Disease Type/Etiology
  - 16.11.3. Severity/Classification
  - 16.11.4. Treatment Type
  - 16.11.5. Route of Administration
  - 16.11.6. Patient Age Group
  - 16.11.7. Distribution Channel
  - 16.11.8. End-Users
- 16.12. Vietnam Global Short Bowel Syndrome Market
  - 16.12.1. Country Segmental Analysis
  - 16.12.2. Disease Type/Etiology
  - 16.12.3. Severity/Classification
  - 16.12.4. Treatment Type
  - 16.12.5. Route of Administration
  - 16.12.6. Patient Age Group
  - 16.12.7. Distribution Channel
  - 16.12.8. End-Users
- 16.13. Rest of Asia Pacific Global Short Bowel Syndrome Market
  - 16.13.1. Country Segmental Analysis
  - 16.13.2. Disease Type/Etiology
  - 16.13.3. Severity/Classification
  - 16.13.4. Treatment Type
  - 16.13.5. Route of Administration
  - 16.13.6. Patient Age Group
  - 16.13.7. Distribution Channel
  - 16.13.8. End-Users
17. Middle East Global Short Bowel Syndrome Market Analysis
- 17.1. Key Segment Analysis
- 17.2. Regional Snapshot
- 17.3. Middle East Global Short Bowel Syndrome Market Size (Value - USD Bn), Analysis, and Forecasts, 2021-2035
  - 17.3.1. Disease Type/Etiology
  - 17.3.2. Severity/Classification
  - 17.3.3. Treatment Type
  - 17.3.4. Route of Administration
  - 17.3.5. Patient Age Group
  - 17.3.6. Distribution Channel
  - 17.3.7. End-Users
  - 17.3.8. Country
    - 17.3.8.1. Turkey
    - 17.3.8.2. UAE
    - 17.3.8.3. Saudi Arabia
    - 17.3.8.4. Israel
    - 17.3.8.5. Rest of Middle East
- 17.4. Turkey Global Short Bowel Syndrome Market
  - 17.4.1. Country Segmental Analysis
  - 17.4.2. Disease Type/Etiology
  - 17.4.3. Severity/Classification
  - 17.4.4. Treatment Type
  - 17.4.5. Route of Administration
  - 17.4.6. Patient Age Group
  - 17.4.7. Distribution Channel
  - 17.4.8. End-Users
- 17.5. UAE Global Short Bowel Syndrome Market
  - 17.5.1. Country Segmental Analysis
  - 17.5.2. Disease Type/Etiology
  - 17.5.3. Severity/Classification
  - 17.5.4. Treatment Type
  - 17.5.5. Route of Administration
  - 17.5.6. Patient Age Group
  - 17.5.7. Distribution Channel
  - 17.5.8. End-Users
- 17.6. Saudi Arabia Global Short Bowel Syndrome Market
  - 17.6.1. Country Segmental Analysis
  - 17.6.2. Disease Type/Etiology
  - 17.6.3. Severity/Classification
  - 17.6.4. Treatment Type
  - 17.6.5. Route of Administration
  - 17.6.6. Patient Age Group
  - 17.6.7. Distribution Channel
  - 17.6.8. End-Users
- 17.7. Israel Global Short Bowel Syndrome Market
  - 17.7.1. Country Segmental Analysis
  - 17.7.2. Disease Type/Etiology
  - 17.7.3. Severity/Classification
  - 17.7.4. Treatment Type
  - 17.7.5. Route of Administration
  - 17.7.6. Patient Age Group
  - 17.7.7. Distribution Channel
  - 17.7.8. End-Users
- 17.8. Rest of Middle East Global Short Bowel Syndrome Market
  - 17.8.1. Country Segmental Analysis
  - 17.8.2. Disease Type/Etiology
  - 17.8.3. Severity/Classification
  - 17.8.4. Treatment Type
  - 17.8.5. Route of Administration
  - 17.8.6. Patient Age Group
  - 17.8.7. Distribution Channel
  - 17.8.8. End-Users
18. Africa Global Short Bowel Syndrome Market Analysis
- 18.1. Key Segment Analysis
- 18.2. Regional Snapshot
- 18.3. Africa Global Short Bowel Syndrome Market Size (Value - USD Bn), Analysis, and Forecasts, 2021-2035
  - 18.3.1. Disease Type/Etiology
  - 18.3.2. Severity/Classification
  - 18.3.3. Treatment Type
  - 18.3.4. Route of Administration
  - 18.3.5. Patient Age Group
  - 18.3.6. Distribution Channel
  - 18.3.7. End-Users
  - 18.3.8. Country
    - 18.3.8.1. South Africa
    - 18.3.8.2. Egypt
    - 18.3.8.3. Nigeria
    - 18.3.8.4. Algeria
    - 18.3.8.5. Rest of Africa
- 18.4. South Africa Global Short Bowel Syndrome Market
  - 18.4.1. Country Segmental Analysis
  - 18.4.2. Disease Type/Etiology
  - 18.4.3. Severity/Classification
  - 18.4.4. Treatment Type
  - 18.4.5. Route of Administration
  - 18.4.6. Patient Age Group
  - 18.4.7. Distribution Channel
  - 18.4.8. End-Users
- 18.5. Egypt Global Short Bowel Syndrome Market
  - 18.5.1. Country Segmental Analysis
  - 18.5.2. Disease Type/Etiology
  - 18.5.3. Severity/Classification
  - 18.5.4. Treatment Type
  - 18.5.5. Route of Administration
  - 18.5.6. Patient Age Group
  - 18.5.7. Distribution Channel
  - 18.5.8. End-Users
- 18.6. Nigeria Global Short Bowel Syndrome Market
  - 18.6.1. Country Segmental Analysis
  - 18.6.2. Disease Type/Etiology
  - 18.6.3. Severity/Classification
  - 18.6.4. Treatment Type
  - 18.6.5. Route of Administration
  - 18.6.6. Patient Age Group
  - 18.6.7. Distribution Channel
  - 18.6.8. End-Users
- 18.7. Algeria Global Short Bowel Syndrome Market
  - 18.7.1. Country Segmental Analysis
  - 18.7.2. Disease Type/Etiology
  - 18.7.3. Severity/Classification
  - 18.7.4. Treatment Type
  - 18.7.5. Route of Administration
  - 18.7.6. Patient Age Group
  - 18.7.7. Distribution Channel
  - 18.7.8. End-Users
- 18.8. Rest of Africa Global Short Bowel Syndrome Market
  - 18.8.1. Country Segmental Analysis
  - 18.8.2. Disease Type/Etiology
  - 18.8.3. Severity/Classification
  - 18.8.4. Treatment Type
  - 18.8.5. Route of Administration
  - 18.8.6. Patient Age Group
  - 18.8.7. Distribution Channel
  - 18.8.8. End-Users
19. South America Global Short Bowel Syndrome Market Analysis
- 19.1. Key Segment Analysis
- 19.2. Regional Snapshot
- 19.3. Central and South Africa Global Short Bowel Syndrome Market Size (Value - USD Bn), Analysis, and Forecasts, 2021-2035
  - 19.3.1. Disease Type/Etiology
  - 19.3.2. Severity/Classification
  - 19.3.3. Treatment Type
  - 19.3.4. Route of Administration
  - 19.3.5. Patient Age Group
  - 19.3.6. Distribution Channel
  - 19.3.7. End-Users
  - 19.3.8. Country
    - 19.3.8.1. Brazil
    - 19.3.8.2. Argentina
    - 19.3.8.3. Rest of South America
- 19.4. Brazil Global Short Bowel Syndrome Market
  - 19.4.1. Country Segmental Analysis
  - 19.4.2. Disease Type/Etiology
  - 19.4.3. Severity/Classification
  - 19.4.4. Treatment Type
  - 19.4.5. Route of Administration
  - 19.4.6. Patient Age Group
  - 19.4.7. Distribution Channel
  - 19.4.8. End-Users
- 19.5. Argentina Global Short Bowel Syndrome Market
  - 19.5.1. Country Segmental Analysis
  - 19.5.2. Disease Type/Etiology
  - 19.5.3. Severity/Classification
  - 19.5.4. Treatment Type
  - 19.5.5. Route of Administration
  - 19.5.6. Patient Age Group
  - 19.5.7. Distribution Channel
  - 19.5.8. End-Users
- 19.6. Rest of South America Global Short Bowel Syndrome Market
  - 19.6.1. Country Segmental Analysis
  - 19.6.2. Disease Type/Etiology
  - 19.6.3. Severity/Classification
  - 19.6.4. Treatment Type
  - 19.6.5. Route of Administration
  - 19.6.6. Patient Age Group
  - 19.6.7. Distribution Channel
  - 19.6.8. End-Users
20. Key Players/ Company Profile
- 20.1. Abbott Laboratories
  - 20.1.1. Company Details/ Overview
  - 20.1.2. Company Financials
  - 20.1.3. Key Customers and Competitors
  - 20.1.4. Business/ Industry Portfolio
  - 20.1.5. Product Portfolio/ Specification Details
  - 20.1.6. Pricing Data
  - 20.1.7. Strategic Overview
  - 20.1.8. Recent Developments
- 20.2. Ardelyx Inc.
- 20.3. B. Braun Melsungen AG
- 20.4. Baxter International Inc.
- 20.5. Danone Nutricia
- 20.6. Emmaus Life Sciences
- 20.7. Fresenius Kabi AG
- 20.8. GlyPharma Therapeutic Inc.
- 20.9. Grifols S.A.
- 20.10. Helsinn Healthcare SA
- 20.11. Ironwood Pharmaceuticals Inc.
- 20.12. Medinova AG
- 20.13. Merck & Co. Inc.
- 20.14. Naia Rare Diseases
- 20.15. Nestlé Health Science
- 20.16. Novartis AG
- 20.17. Nutrinia Ltd
- 20.18. Otsuka Pharmaceutical Co. Ltd.
- 20.19. OxThera AB
- 20.20. Pfizer Inc.
- 20.21. Sanofi S.A.
- 20.22. Takeda Pharmaceutical Company Limited
- 20.23. VectivBio AG
- 20.24. Zealand Pharma A/S
- 20.25. Other Key Players

Note* - This is just tentative list of players. While providing the report, we will cover more number of players based on their revenue and share for each geography

Get PDF

PRICING DETAILS

Single-User Upto 2 Users - [PDF + Excel Only]

USD 4150

Multi-User Upto 10 Users - [PDF + Excel + PPT]

USD 5950

Enterprise-User Company-wide - [Report Pack + Benchmark + 6M Update]

USD 7750

Related Report

Discount On Multiple Reports

Where did We Help Most?

Custom Market Research Services

We will customise the research for you, in case the report listed above does not meet your requirements.

Get 10% Free Customisation